^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR G719C

i
Entrez ID:
Phase 3
National Cancer Institute, Naples
Active, not recruiting
Last update posted :
03/24/2023
Initiation :
04/01/2016
Primary completion :
12/01/2023
Completion :
07/01/2024
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
|
Avastin (bevacizumab) • erlotinib
Phase 2
Fondazione Ricerca Traslazionale
Recruiting
Last update posted :
02/21/2023
Initiation :
06/12/2020
Primary completion :
12/31/2023
Completion :
12/31/2023
EGFR • HER-2 • BRAF • ALK • MET • ROS1
|
EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
|
Tagrisso (osimertinib) • Vizimpro (dacomitinib)
Phase N/A
Wenzhou Medical University
Unknown status
Last update posted :
11/01/2016
Initiation :
05/01/2016
Primary completion :
12/01/2017
Completion :
06/01/2018
EGFR
|
EGFR mutation • EGFR L858R • EGFR L861Q • EGFR G719A • EGFR G719S • EGFR G719C • EGFR exon 19 insertion
|
gefitinib